Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Buparlisib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 11 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
- 24 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Feb 2015 Status changed from not yet recruiting to recruiting, as reported by National Cancer Institute of Canada record.